PepGen Inc. (PEPG)

NMS – Real vaqt narxi. Valyuta: USD

2.92

+0.03 (0.86%)

Bozor ochiq: Aug 12, 2026, 1:14 PM EDT

2.90

-0.00 (-0.17%)

Oldingi bozordan keyin: Aug 11, 2026, 7:34 PM EDT

06.08.2026

PepGen Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

BOSTON--(BUSINESS WIRE)---- $PEPG #DM1--PepGen Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights.

06.08.2026

PepGen to Advance PGN-EDODM1 Into Highest Dose Cohort in Phase 2 FREEDOM2-DM1 Study Following DSMB Review

BOSTON--(BUSINESS WIRE)---- $PEPG #DM1--PepGen to Advance PGN-EDODM1 into Highest Dose Cohort in Phase 2 FREEDOM2-DM1 Study Following DSMB Review.

Videolar

No Data

There is no data to display

Press-relizlar

06.08.2026

PepGen Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

BOSTON--(BUSINESS WIRE)---- $PEPG #DM1--PepGen Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights.

06.08.2026

PepGen to Advance PGN-EDODM1 Into Highest Dose Cohort in Phase 2 FREEDOM2-DM1 Study Following DSMB Review

BOSTON--(BUSINESS WIRE)---- $PEPG #DM1--PepGen to Advance PGN-EDODM1 into Highest Dose Cohort in Phase 2 FREEDOM2-DM1 Study Following DSMB Review.

PepGen Inc. (PEPG)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

PepGen Inc. (PEPG)

PepGen Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

PepGen to Advance PGN-EDODM1 Into Highest Dose Cohort in Phase 2 FREEDOM2-DM1 Study Following DSMB Review

Videolar

No Data

Press-relizlar

PepGen Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

PepGen to Advance PGN-EDODM1 Into Highest Dose Cohort in Phase 2 FREEDOM2-DM1 Study Following DSMB Review

PepGen Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

PepGen to Advance PGN-EDODM1 Into Highest Dose Cohort in Phase 2 FREEDOM2-DM1 Study Following DSMB Review

Videolar

No Data

Press-relizlar

PepGen Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

PepGen to Advance PGN-EDODM1 Into Highest Dose Cohort in Phase 2 FREEDOM2-DM1 Study Following DSMB Review

Search stocks

PepGen Inc. (PEPG)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

PepGen Inc. (PEPG)

PepGen Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

PepGen to Advance PGN-EDODM1 Into Highest Dose Cohort in Phase 2 FREEDOM2-DM1 Study Following DSMB Review

Videolar

No Data

Press-relizlar

PepGen Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

PepGen to Advance PGN-EDODM1 Into Highest Dose Cohort in Phase 2 FREEDOM2-DM1 Study Following DSMB Review

PepGen Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

PepGen to Advance PGN-EDODM1 Into Highest Dose Cohort in Phase 2 FREEDOM2-DM1 Study Following DSMB Review

Videolar

No Data

Press-relizlar

PepGen Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

PepGen to Advance PGN-EDODM1 Into Highest Dose Cohort in Phase 2 FREEDOM2-DM1 Study Following DSMB Review